MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]

MS Australia’s 2025-26 Pre-Budget Submission advocates for strategic investments to support over 33,300 Australians living with MS. Key funding asks include $8M for a National MS Biobank, $300M [...]

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]